ADUS vs CHE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ADUS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ADUS and CHE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ADUS and CHE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Addus HomeCare Corporation provides in-home care to elderly, chronically ill, and disabled people through three segments: personal care (help with bathing, dressing, meals, and daily activities), hospice (end-of-life care), and home health (skilled nursing and therapy). Personal care is by far the largest piece at roughly 77% of revenue and is funded predominantly by state Medicaid programs, while hospice and home health are largely Medicare-funded. The company operates across many states with heavy concentration in markets like Illinois, New Mexico, and Texas, and has grown for years through a steady stream of acquisitions, most recently a large personal care deal that lifted 2025 revenue sharply.

Full ADUS guide

Chemed Corporation runs two entirely unrelated businesses under one holding company. VITAS Healthcare, roughly two-thirds of revenue, is a leading provider of end-of-life hospice and palliative care, drawing well over 90% of its revenue from Medicare and Medicaid per-diem payments. Roto-Rooter, the remaining third, is the largest US provider of plumbing, drain cleaning, and water-damage restoration, serving both residential and commercial customers through company-owned operations and franchises. The two segments share little operationally but together produce steady consolidated cash flow that management returns via buybacks and a small dividend.

Full CHE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ADUS drivers: Aging demographics and shift to home; Personal care volume and rate growth.
• CHE drivers: VITAS hospice demand and aging demographics; Reduced Medicare Cap drag.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The largest risk is reimbursement concentration: personal care depends heavily on state Medicaid budgets and hospice and home health on Medicare, so rate cuts, budget shortfalls, or eligibility changes in key states can pressure revenue and margins directly. For CHE, vITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ADUS if you believe its drivers more; CHE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ADUS and CHE guides.

ADUS. Addus trades at a low-20s trailing earnings multiple, reflecting a steady, profitable services operator rather than a high-growth name. First quarter 2026 revenue of roughly $363.6 million missed some estimates while adjusted EPS beat, and net income rose about 18% year over year. The 2025 revenue jump was driven mostly by a large personal care acquisition, so underlying organic growth runs closer to mid-single digits.

CHE. Chemed posted 2025 revenue of about $2.53 billion (up ~4%) with net income near $265 million, and Q1 2026 consolidated revenue of roughly $657 million split about $420 million VITAS and $237 million Roto-Rooter. The stock traded near $480 in early July 2026, giving a market cap around $6 billion and a trailing P/E in the low-20s. Management raised full-year 2026 adjusted EPS guidance to roughly $23.25 to $24.25.

Headline figures (approximate, July 2026): ADUS shows revenue (ttm) ~$1.44B, fy2025 revenue ~$1.42B (up ~23%), q1 2026 revenue ~$363.6M (up ~7.7%), q1 2026 adjusted eps ~$1.62 (up ~14%); CHE shows revenue (ttm) ~$2.5B, net income (fy2025) ~$265M, free cash flow (fy2025, after capex) ~$325M, 2026 adjusted eps guidance ~$23.25-$24.25.

ADUS and CHE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ADUS and CHE exposure against your real portfolio. It is not an investment adviser.